Supplementary Figure 1 from Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer

Abstract

The toxicity profiles were similar between the treatment arms. (A) There was no difference in the total number of graded adverse events (AE) between arms of the trial. (B) There was no significant difference in the maximum local and systemic toxicity experienced by each patient between arms of the trial.